Yun Zhong
Stock Analyst at Wedbush
(4.06)
# 549
Out of 5,124 analysts
44
Total ratings
56.41%
Success rate
12.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $33 | $15.00 | +120.00% | 3 | Dec 12, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Outperform | $32 | $21.07 | +51.87% | 12 | Dec 9, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $220 | $213.15 | +3.21% | 3 | Nov 18, 2025 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $17.92 | -10.71% | 3 | Nov 6, 2025 | |
| IRD Opus Genetics | Initiates: Outperform | $8 | $2.13 | +275.59% | 1 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $84.18 | +2.16% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $11.19 | +60.86% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $16.11 | +148.29% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $5.54 | +405.42% | 1 | Aug 11, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Outperform | $9 → $8 | $4.08 | +96.08% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $5.99 | +33.56% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $3.55 | +801.41% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $1.97 | +510.69% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $3.95 | +608.86% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.89 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $14.25 | +12.28% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $22.63 | +103.27% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.48 | +1,980.73% | 1 | May 5, 2021 |
Wave Life Sciences
Dec 12, 2025
Maintains: Outperform
Price Target: $20 → $33
Current: $15.00
Upside: +120.00%
Sarepta Therapeutics
Dec 9, 2025
Initiates: Outperform
Price Target: $32
Current: $21.07
Upside: +51.87%
Ascendis Pharma
Nov 18, 2025
Reiterates: Outperform
Price Target: $220
Current: $213.15
Upside: +3.21%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $17.92
Upside: -10.71%
Opus Genetics
Oct 29, 2025
Initiates: Outperform
Price Target: $8
Current: $2.13
Upside: +275.59%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $84.18
Upside: +2.16%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $11.19
Upside: +60.86%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $16.11
Upside: +148.29%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $5.54
Upside: +405.42%
Voyager Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.08
Upside: +96.08%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $5.99
Upside: +33.56%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.55
Upside: +801.41%
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $1.97
Upside: +510.69%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $3.95
Upside: +608.86%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.89
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $14.25
Upside: +12.28%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $22.63
Upside: +103.27%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.48
Upside: +1,980.73%